ERBB2 and neoplasm: Results from a randomized phase III trial (NCT03615326) support the efficacy of pembrolizumab plus trastuzumab-including chemotherapy in Her2 positive GACs, with a significant reduction in tumor size and improvement in objective response rate (ORR); complete responses in some participants have also been reported [47].